Antidiabetic treatment, obesity, and cancer risk in Algerian patients with type 2 diabetes mellitus
OBJECTIVE: Several studies have shown that antidiabetic drugs and obesity can modulate the risk of developing cancer. The objective of this study was to assess the impact of the use of antidiabetic drugs and obesity on the risk of developing cancers in type 2 diabetics. MATERIALS AND METHODS: Data...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2022-09-01
|
| Series: | World Cancer Research Journal |
| Subjects: | |
| Online Access: | https://www.wcrj.net/wp-content/uploads/sites/5/2022/09/e2394.pdf |
| _version_ | 1811293472760528896 |
|---|---|
| author | N. Dennouni-Medjati M. Dali-Sahi B. Guermouche H. Merad Boudia F. Djelti Y. Harek Y. Kachekouche |
| author_facet | N. Dennouni-Medjati M. Dali-Sahi B. Guermouche H. Merad Boudia F. Djelti Y. Harek Y. Kachekouche |
| author_sort | N. Dennouni-Medjati |
| collection | DOAJ |
| description | OBJECTIVE: Several studies have shown that antidiabetic drugs and obesity can modulate the risk of developing cancer. The objective of this study was to assess the impact of the use of antidiabetic drugs and obesity on the risk of developing cancers in type 2 diabetics.
MATERIALS AND METHODS: Data for 1220 patients were collected from the processing of files and a pre-established questionnaire. The anthropobiological parameters and the associated treatment type have been unspecified.
RESULTS: Women (OR=17.26; 95% CI=2.88-103.45, p<0.01), overweight individuals (OR=4.81; 95% CI=1.63-14.14, p<0.01) and hypertensive diabetic subjects (OR=3.82; 95% CI=1.39-10.49, p< 0.01) are more exposed to cancers. It is interesting to note that diabetic subjects treated with insulin have a reduced risk of developing cancer (OR=0.22; 95% CI=0.07-0.67, p<0.01). Diabetic subjects treated with metformin have a four and a half times higher risk of developing cancer (OR=4.61; 95% CI=1.48-14.37, p<0.01).
CONCLUSIONS: In type 2 diabetic subjects, cancer is significantly linked to overweight, to the presence of essential hypertension in individuals under hypotensive as well as in patients treated with metformin. |
| first_indexed | 2024-04-13T05:01:57Z |
| format | Article |
| id | doaj.art-9a4228b9560045caa2d3de3e819c3aab |
| institution | Directory Open Access Journal |
| issn | 2372-3416 |
| language | English |
| last_indexed | 2024-04-13T05:01:57Z |
| publishDate | 2022-09-01 |
| publisher | Verduci Editore |
| record_format | Article |
| series | World Cancer Research Journal |
| spelling | doaj.art-9a4228b9560045caa2d3de3e819c3aab2022-12-22T03:01:19ZengVerduci EditoreWorld Cancer Research Journal2372-34162022-09-01910.32113/wcrj_20229_23942394Antidiabetic treatment, obesity, and cancer risk in Algerian patients with type 2 diabetes mellitusN. Dennouni-Medjati0M. Dali-Sahi1B. Guermouche2H. Merad Boudia3F. Djelti4Y. Harek5Y. Kachekouche6Department of Biology, University of Tlemcen, Tlemcen, AlgeriaDepartment of Biology, University of Tlemcen, Tlemcen, AlgeriaDepartment of Biology, University of Tlemcen, Tlemcen, AlgeriaDepartment of Biology, University of Tlemcen, Tlemcen, AlgeriaDepartment of Biology, University of Tlemcen, Tlemcen, AlgeriaAnalytical Chemistry and Electrochemistry Laboratory, University of Tlemcen, Tlemcen, AlgeriaDepartment of Biology, University of Tlemcen, Tlemcen, AlgeriaOBJECTIVE: Several studies have shown that antidiabetic drugs and obesity can modulate the risk of developing cancer. The objective of this study was to assess the impact of the use of antidiabetic drugs and obesity on the risk of developing cancers in type 2 diabetics. MATERIALS AND METHODS: Data for 1220 patients were collected from the processing of files and a pre-established questionnaire. The anthropobiological parameters and the associated treatment type have been unspecified. RESULTS: Women (OR=17.26; 95% CI=2.88-103.45, p<0.01), overweight individuals (OR=4.81; 95% CI=1.63-14.14, p<0.01) and hypertensive diabetic subjects (OR=3.82; 95% CI=1.39-10.49, p< 0.01) are more exposed to cancers. It is interesting to note that diabetic subjects treated with insulin have a reduced risk of developing cancer (OR=0.22; 95% CI=0.07-0.67, p<0.01). Diabetic subjects treated with metformin have a four and a half times higher risk of developing cancer (OR=4.61; 95% CI=1.48-14.37, p<0.01). CONCLUSIONS: In type 2 diabetic subjects, cancer is significantly linked to overweight, to the presence of essential hypertension in individuals under hypotensive as well as in patients treated with metformin.https://www.wcrj.net/wp-content/uploads/sites/5/2022/09/e2394.pdftype 2 diabetes mellituscanceroverweightinsulinmetformin |
| spellingShingle | N. Dennouni-Medjati M. Dali-Sahi B. Guermouche H. Merad Boudia F. Djelti Y. Harek Y. Kachekouche Antidiabetic treatment, obesity, and cancer risk in Algerian patients with type 2 diabetes mellitus World Cancer Research Journal type 2 diabetes mellitus cancer overweight insulin metformin |
| title | Antidiabetic treatment, obesity, and cancer risk in Algerian patients with type 2 diabetes mellitus |
| title_full | Antidiabetic treatment, obesity, and cancer risk in Algerian patients with type 2 diabetes mellitus |
| title_fullStr | Antidiabetic treatment, obesity, and cancer risk in Algerian patients with type 2 diabetes mellitus |
| title_full_unstemmed | Antidiabetic treatment, obesity, and cancer risk in Algerian patients with type 2 diabetes mellitus |
| title_short | Antidiabetic treatment, obesity, and cancer risk in Algerian patients with type 2 diabetes mellitus |
| title_sort | antidiabetic treatment obesity and cancer risk in algerian patients with type 2 diabetes mellitus |
| topic | type 2 diabetes mellitus cancer overweight insulin metformin |
| url | https://www.wcrj.net/wp-content/uploads/sites/5/2022/09/e2394.pdf |
| work_keys_str_mv | AT ndennounimedjati antidiabetictreatmentobesityandcancerriskinalgerianpatientswithtype2diabetesmellitus AT mdalisahi antidiabetictreatmentobesityandcancerriskinalgerianpatientswithtype2diabetesmellitus AT bguermouche antidiabetictreatmentobesityandcancerriskinalgerianpatientswithtype2diabetesmellitus AT hmeradboudia antidiabetictreatmentobesityandcancerriskinalgerianpatientswithtype2diabetesmellitus AT fdjelti antidiabetictreatmentobesityandcancerriskinalgerianpatientswithtype2diabetesmellitus AT yharek antidiabetictreatmentobesityandcancerriskinalgerianpatientswithtype2diabetesmellitus AT ykachekouche antidiabetictreatmentobesityandcancerriskinalgerianpatientswithtype2diabetesmellitus |